Leo Labs Drug Patent Portfolio
Leo Labs owns 1 orange book drug protected by 16 US patents Given below is the list of Leo Labs's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9789078 | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy | 15 May, 2033 | Active |
| US8278292 | Therapeutic compositions | 06 Jul, 2027 | Active |
| US8372827 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US8372828 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US8377919 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US8536163 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US8716271 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US8735375 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US9820959 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US9833428 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US9833429 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US9861603 | Therapeutic compositions | 18 Dec, 2026 | Active |
| US6844013 | Methods of stimulating the immune system | 13 Dec, 2018 | Expired |
| US6432452 | Anti-cancer compounds | 19 Aug, 2018 | Expired |
| US6787161 | Anti-cancer compounds | 19 Aug, 2018 | Expired |
| US7410656 | Anti-cancer compounds | 19 Aug, 2018 | Expired |
Latest Legal Activities on Leo Labs's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Leo Labs.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8278292 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US9789078 |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US9833429 |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US9820959 |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US9833428 |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US9861603 |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8735375 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8716271 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8372828 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8536163 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8372827 (Litigated) |
|
Correspondence Address Change
Critical
| 26 Jun, 2024 | US8377919 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 20 May, 2024 | US8278292 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Dec, 2021 | US8735375 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2021 | US8716271 (Litigated) |
Leo Labs Drug Patents' Oppositions Filed in EPO
Leo Labs drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 11, 2014, by Sandoz Ag. This opposition was filed on patent number EP06820561A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06820561A | Nov, 2014 | Actavis PTC ehf | Revoked |
| EP06820561A | Nov, 2014 | Galenicum Health S.L. | Revoked |
| EP06820561A | Nov, 2014 | Sandoz AG | Revoked |
Leo Labs's Family Patents
Leo Labs drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 37.2% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Leo Labs Drug List
Given below is the complete list of Leo Labs's drugs and the patents protecting them.
1. Picato
Picato is protected by 16 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9789078 | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
15 May, 2033
(8 years from now)
| Active |
| US8278292 | Therapeutic compositions |
06 Jul, 2027
(2 years from now)
| Active |
| US8372827 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US8372828 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US8377919 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US8536163 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US8716271 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US8735375 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US9820959 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US9833428 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US9833429 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US9861603 | Therapeutic compositions |
18 Dec, 2026
(2 years from now)
| Active |
| US6844013 | Methods of stimulating the immune system |
13 Dec, 2018
(5 years ago)
| Expired |
| US6432452 | Anti-cancer compounds |
19 Aug, 2018
(6 years ago)
| Expired |
| US6787161 | Anti-cancer compounds |
19 Aug, 2018
(6 years ago)
| Expired |
| US7410656 | Anti-cancer compounds |
19 Aug, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Picato's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List